Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
An MC4R (melanocortin 4 receptor) agonist FDA-approved for rare genetic obesity disorders including POMC, PCSK1, and LEPR deficiency. Represents a precision medicine approach to obesity treatment.
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
Activates the MC4R pathway in the hypothalamus, restoring satiety signaling that is disrupted in specific genetic obesity conditions. Unlike GLP-1 agonists, it targets the melanocortin pathway directly.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
- Rare genetic obesity (POMC deficiency)
- PCSK1 deficiency obesity
- LEPR deficiency obesity
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- Skin hyperpigmentation (common)
- Injection site reactions
- Depression and suicidal ideation (boxed warning)
- Spontaneous penile erections
- Very narrow approved indication
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
FDA-approved as Imcivree (2020) for chronic weight management in patients 6+ years with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. Not approved for general obesity.
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
- Setmelanotide for POMC deficiency obesity
2020 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.